Engineering Polymer-Binding Bispecific Antibodies for Enhanced Pretargeted Delivery of Nanoparticles to Mucus-Covered Epithelium

Angewandte Chemie
Justin T HuckabySamuel K Lai

Abstract

Mucus represents a major barrier to sustained and targeted drug delivery to mucosal epithelium. Ideal drug carriers should not only rapidly diffuse across mucus, but also bind the epithelium. Unfortunately, ligand-conjugated particles often exhibit poor penetration across mucus. In this work, we explored a two-step "pretargeting" approach through engineering a bispecific antibody that binds both cell-surface ICAM-1 and polyethylene glycol (PEG) on the surface of nanoparticles, thereby effectively decoupling cell targeting from particle design and formulation. When tested in a mucus-coated Caco-2 culture model that mimics the physiological process of mucus clearance, pretargeting increased the amount of PEGylated particles binding to cells by around 2-fold or more compared to either non-targeted or actively targeted PEGylated particles. Pretargeting also markedly enhanced particle retention in mouse intestinal tissues. Our work underscores pretargeting as a promising strategy to improve the delivery of therapeutics to mucosal surfaces.

References

Apr 1, 1992·Pharmaceutical Research·C M LehrH E Junginger
Nov 1, 1996·Pharmaceutical Research·J M IracheG Ponchel
Sep 1, 2000·Advanced Drug Delivery Reviews·M A ClarkM A Jepson
Nov 3, 2004·Advanced Drug Delivery Reviews·Junghae SuhJustin Hanes
Nov 14, 2006·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yashu YinHaiyang Hu
Jan 25, 2007·Proceedings of the National Academy of Sciences of the United States of America·Samuel K LaiJustin Hanes
Jan 10, 2009·Advanced Drug Delivery Reviews·Samuel K LaiJustin Hanes
Jan 13, 2009·Advanced Drug Delivery Reviews·Richard A Cone
Dec 19, 2009·Proceedings of the National Academy of Sciences of the United States of America·Samuel K LaiJustin Hanes
Apr 15, 2010·Angewandte Chemie·Raffaella RossinMarc S Robillard
Apr 29, 2010·Cancer Biotherapy & Radiopharmaceuticals·Roland B WalterJohn M Pagel
Jul 22, 2010·Angewandte Chemie·Katrin KnopUlrich S Schubert
Jun 28, 2012·Theranostics·David M GoldenbergRobert M Sharkey
Nov 22, 2013·Molecular Pharmaceutics·Xi ZhuYuan Huang
Jan 28, 2014·Nature Biotechnology·Steven M LewisStephen J Demarest
Apr 11, 2015·Advanced Drug Delivery Reviews·Benjamin S SchusterJustin Hanes
May 23, 2015·Nature Reviews. Cancer·Steven M LarsonOliver W Press
Sep 29, 2015·Journal of Nanoscience and Nanotechnology·C Cruje, B D Chithrani
Apr 14, 2016·Scientific Reports·Sudath HapuarachchigeDmitri Artemov
Apr 2, 2017·Journal of Controlled Release : Official Journal of the Controlled Release Society·Qi YangSamuel K Lai
Sep 9, 2017·Advanced Drug Delivery Reviews·Justin T Huckaby, Samuel K Lai
Nov 7, 2017·Advanced Drug Delivery Reviews·Xabier MurgiaClaus-Michael Lehr
Nov 9, 2017·Advanced Drug Delivery Reviews·María García-DíazHanne Mørck Nielsen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Related Papers

Journal of Controlled Release : Official Journal of the Controlled Release Society
Olcay MertJustin Hanes
Journal of Controlled Release : Official Journal of the Controlled Release Society
Jung Soo SukJustin Hanes
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V
Juliane AnderskiKlaus Langer
© 2022 Meta ULC. All rights reserved